SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    ) Wiegandt , H. Gangliosides . In “ Glycolipids ,” ed. H. Wiegandt , pp. 199260 ( 1985 ). Elsevier Science Publishers, B. V. , Amsterdam .
  • 2
    ) Suzuki , K. The pattern of mammalian brain gangliosides. II. Evaluation of the extraction procedures, postmortem changes and the effect of formalin preservation . J. Neurochem. , 12 , 629638 ( 1965 ).
  • 3
    ) Portoukalian , J. , Zwingelstein , G. and Dore , J. F. Lipid composition of human malignant melanoma tumors at various levels of malignant growth . Eur. J. Biochem. , 94 , 1923 ( 1979 ).
  • 4
    ) Carubia , J. M. , Yu , R. K. , Macala , L. J. , Kirkwood , J. M. and Varga , J. M. Gangliosides of normal and neoplastic human melanocytes . Biochem. Biophys. Res. Commun. , 120 , 500504 ( 1984 ).
  • 5
    ) Cheung , N. K. , Sarrinen , U. M. , Neely , J. E. , Landmeier , B. , Donovan , D. and Coccia , P. F. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells . Cancer Res. , 45 , 26422649 ( 1985 ).
  • 6
    ) Fredman , P. , von Hoist , H. , Collins , V. P. , Ammar , A. , Dellheden , B. , Wahren , B. , Granholm , L. and Svennerholm , L. Potential ganglioside antigens associated with human gliomas . Neural. Res. , 8 , 123126 ( 1986 ).
  • 7
    ) Chang , H. R. , Cordon-Cardo , C. , Houghton , A. N. , Cheung , N. K. and Brennan , M. F. Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas . Cancer (Phila.) , 70 , 633638 ( 1992 ).
  • 8
    ) Yuyama , Y. , Dohi , T. , Morita , H. , Furukawa , K. and Oshima , M. Enhanced expression of GM2/GD2 synthase mRNA in human gastrointestinal cancer . Cancer , 75 , 12731280 ( 1995 ).
  • 9
    ) Dohi , T. , Hanai , N. , Yamaguchi , K. and Oshima , M. Localization of UDP-GalNAc:NeuAc α 2,3Gal-R β1,4(GalNAc to Gal)N-acetylgalactosaminyltransferase in human stomach. Enzymatic synthesis of a fundic gland-specific ganglioside and GM2 . J. Biol. Chem. , 266 , 2403824043 ( 1991 ).
  • 10
    ) Merritt , W. D. , Sztein , M. B. and Reaman , G. H. Detection of GD3 ganglioside in childhood acute lymphoblastic leukemia with monoclonal antibody to GD3: restriction to immunophenotypically defined T-cell disease . J. Cell. Biochem. , 37 , 1119 ( 1988 ).
  • 11
    ) Furukawa , K. , Akagi , T. , Nagata , Y. , Yamada , Y. , Shimotohno , K. , Cheung , N. K. , Shiku , H. and Furukawa , K. GD2 ganglioside on human T-lymphotropic virus type I-infected T cells: possible activation of β–1,4–N-acetylgalactosaminyltransferase gene by p40tax . Proc. Natl. Acad. Sci. USA , 90 , 19721976 ( 1993 ).
  • 12
    ) Okada , M. , Furukawa , K. , Yamashiro , S. , Yamada , Y. , Haraguchi , M. , Horibe , K. , Kato , K. , Tsuji , Y. and Furukawa , K. High expression of ganglioside α–2,8–sialyl-transferase (GD3 synthase) gene in adult T-cell leukemia cells unrelated to the gene expression of human T-lymphotropic virus type I . Cancer Res. , 56 , 28442848 ( 1996 ).
  • 13
    ) Cheresh , D. A. , Rosenberg , J. , Mujoo , K. , Hirschowitz , L. and Reisfeld , R. A. Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis . Cancer Res. , 46 , 51125118 ( 1986 ).
  • 14
    ) Dnistrian , A. M. and Schwartz , M. K. Lipid-bound sialic acid as a tumor marker . Ann. Clin. Lab. Sci. , 13 , 137142 ( 1983 ).
  • 15
    ) Sung , C. C. , Pearl , D. K. , Coons , S. W. , Scheithauer , B. W. , Johnson , P. C. and Yates , A. J. Gangliosides as diagnostic markers of human astrocytomas and primitive neuroectodermal tumors . Cancer , 74 , 30103022 ( 1994 ).
  • 16
    ) Nakamori , S. , Furukawa , H. , Hiratsuka , M. , Iwanaga , T. , Imaoka , S. , Ishikawa , O. , Kabuto , T. , Sasaki , Y. , Kameyama , M. , Ishiguro , S. and Irimura , T. Expression of carbohydrate antigen sialyl Le(a): a new functional prognostic factor in gastric cancer . J. Clin. Oncol. , 15 , 816825 ( 1997 ).
  • 17
    ) Sung , C. C. , Pearl , D. K. , Coons , S. W. , Scheithauer , B. W. , Johnson , P. C. , Zheng , M. and Yates , A. J. Correlation of ganglioside patterns of primary brain tumors with survival . Cancer , 75 , 851859 ( 1995 ).
  • 18
    ) Lode , H. N. , Handgretinger , R. , Schuermann , U. , Seitz , G. , Klingebiel , T. , Niethammer , D. and Beck , J. Detection of neuroblastoma cells in CD34+ selected peripheral stem cells using a combination of tyrosine hydroxylase nested RT-PCR and anti-ganglioside GD2 immunocytochemistry . Eur. J. Cancer , 33 , 20242030 ( 1997 ).
  • 19
    ) Houghton , A. N. , Mintzer , D. , Cordon-Cardo , C. , Welt , S. , Fliegel , B. , Vadhan , S. , Carswell , E. , Melamed , M. R. , Oettgen , H. F. and Old , L. J. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma . Proc. Natl. Acad. Sci. USA , 82 , 12421246 ( 1985 ).
  • 20
    ) Irie , R. F. and Morton , D. L. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2 . Proc. Natl. Acad. Sci. USA , 83 , 86948698 ( 1986 ).
  • 21
    ) Cheung , N. K. , Cheung , I. Y. , Canete , A. , Yeh , S. J. , Kushner , B. , Bonilla , M. A. , Heller , G. and Larson , S. M. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival . Cancer Res. , 54 , 22282233 ( 1994 ).
  • 22
    ) Cheung , N. K. , Kushner , B. H. , Yeh , S. D. and Larson , S. M. 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study . Int. J. Oncol. , 12 , 12991306 ( 1998 ).
  • 23
    ) Pegram , M. and Slamon , D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy . Semin. Oncol. , 27 , 1319 ( 2000 ).
  • 24
    ) Treon , S. P. and Anderson , K. C. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders . Semin. Oncol. , 27 , 7985 ( 2000 ).
  • 25
    ) Dickman , S. Antibodies stage a comeback in cancer treatment . Science , 280 , 11961197 ( 1998 ).
  • 26
    ) Cheresh , D. A. , Pierschbacher , M. D. , Herzig , M. A. and Mujoo , K. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins . J. Cell Biol. , 102 , 688696 ( 1986 ).
  • 27
    ) Nakano , J. , Yasui , H. , Lloyd , K. O. and Muto , M. Biologic roles of gangliosides G (M3) and G (D3) in the attachment of human melanoma cells to extracellular matrix proteins . J. Investig. Dermatol. Symp. Proc. , 4 , 173176 ( 1999 ).
  • 28
    ) Dippold , W. G. , Knuth , A. and Meyer Zum , B. K. H. Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3–ganglioside antibody . Cancer Res. , 44 , 806810 ( 1984 ).
  • 29
    ) Nakano , J. , Raj , B. K. , Asagami , C. and Lloyd , K. O. Human melanoma cell lines deficient in GD3 ganglioside expression exhibit altered growth and tumorigenic characteristics . J. Invest. Dermatol. , 107 , 543548 ( 1996 ).
  • 30
    ) Thurin , J. , Thurin , M. , Herlyn , M. , Elder , D. E. , Steplewski , Z. , Clark , W. H. , Jr. and Koprowski , H. GD2 ganglioside biosynthesis is a distinct biochemical event in human melanoma tumor progression . FEBS Lett. , 208 , 1722 ( 1986 ).
  • 31
    ) Yoshida , S. , Fukumoto , S. , Kawaguchi , H. , Sato , S. , Ueda , R. and Furukawa , K. Ganglioside G (D2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis . Cancer Res. , 61 , 42444252 ( 2001 ).
  • 32
    ) Svennerholm , L. Chromatographic separation of human brain gangliosides . J. Neurochem. , 10 , 613623 ( 1963 ).
  • 33
    ) Haraguchi , M. , Yamashiro , S. , Yamamoto , A. , Furukawa , K. , Takamiya , K. , Lloyd , K. O. , Shiku , H. and Furukawa , K. Isolation of GD3 synthase gene by expression cloning of GM3 α–2,8–sialyl-transferase cDNA using anti-GD2 monoclonal antibody . Proc. Natl. Acad. Sci. USA , 91 , 1045510459 ( 1994 ).
  • 34
    ) Miyazaki , H. , Fukumoto , S. , Okada , M. , Hasegawa , T. and Furukawa , K. Expression cloning of rat cDNA encoding UDP-galactose:GD2 β1,3–galactosyltransferase that determines the expression of GD1b/GM1/GA1 . J. Biol. Chem. , 272 , 2479424799 ( 1997 ).
  • 35
    ) Lowry , O. H. , Rosebrough , N. J. , Farr , A. L. and Randall , R. J. Protein measurement with the Folin phenol reagent . J. Biol. Chem. , 193 , 265275 ( 1951 ).
  • 36
    ) Hudson , P. J. Recombinant antibody constructs in cancer therapy . Curr. Opin. Immunol. , 11 , 548557 ( 1999 ).
  • 37
    ) Watanabe , T. , Naito , M. , Kokubu , N. and Tsuruo , T. Regression of established tumors expressing P-glycoprotein by combinations of adriamycin, cyclosporin derivatives, and MRK–16 antibodies . J. Natl. Cancer Inst. , 89 , 512518 ( 1997 ).
  • 38
    ) Mizutani , Y. , Bonavida , B. , Koishihara , Y. , Akamatsu , K. , Ohsugi , Y. and Yoshida , O. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody . Cancer Res. , 55 , 590596 ( 1995 ).
  • 39
    ) Mendelsohn , J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy . Clin. Cancer Res. , 3 , 27032707 ( 1997 ).
  • 40
    ) Ciardiello , F. , Bianco , R. , Damiano , V. , De Lorenzo , S. , Pepe , S. , De Placido , S. , Fan , Z. , Mendelsohn , J. , Bianco , A. R. and Tortora , G. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225 . Clin. Cancer Res. , 5 , 909916 ( 1999 ).
  • 41
    ) Margolin , K. , Gordon , M. S. , Holmgren , E. , Gaudreault , J. , Novotny , W. , Fyfe , G. , Adelman , D. , Stalter , S. and Breed , J. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data . J. Clin. Oncol. , 19 , 851856 ( 2001 ).
  • 42
    ) Pegram , M. D. and Slamon , D. J. Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptorenhanced chemosensitivity . Semin. Oncol. , 26 , 8995 ( 1999 ).
  • 43
    ) Burris , H. A. , 3rd. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer . Semin. Oncol. , 28 , 3844 ( 2001 ).
  • 44
    ) Crown , J. P. The platinum agents: a role in breast cancer treatment ? Semin. Oncol. , 28 , 2837 ( 2001 ).
  • 45
    ) Agus , D. B. , Bunn , P. A. , Jr. , Franklin , W. , Garcia , M. and Ozols , R. F. HER–2/neu as a therapeutic target in nonsmall cell lung cancer, prostate cancer, and ovarian cancer . Semin. Oncol. , 27 , 5363 ( 2000 ).
  • 46
    ) Mizutani , Y. , Okada , Y. , Yoshida , O. , Fukumoto , M. and Bonavida , B. Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity . Cancer , 79 , 11801189 ( 1997 ).
  • 47
    ) Pace , E. , Melis , M. , Siena , L. , Bucchieri , F. , Vignola , A. M. , Profita , M. , Gjomarkaj , M. and Bonsignore , G. Effects of gemcitabine on cell proliferation and apoptosis in non-small-cell lung cancer (NSCLC) cell lines . Cancer Chemother. Phamacol. , 46 , 467476 ( 2000 ).
  • 48
    ) Makin , G. and Hickman , J. A. Apotosis and cancer chemotherapy . Cell Tissue Res. , 301 , 143152 ( 2000 ).
  • 49
    ) Debatin , K. Activation of apoptosis pathways by anticancer treatment . Toxicol. Lett. , 112113 , 41 – 48 ( 2000 ).
  • 50
    ) Lowe , S. W. Cancer therapy and p53 . Curr. Opin. Oncol. , 7 , 547553 ( 1995 ).
  • 51
    ) Fan , S. , el-Deiry , W. S. , Bae , I. , Freeman , J. , Jondle , D. , Bhatia , K. , Fornace , A. J. , Jr. , Magrath , I. , Kohn , K. W. and O'Connor , P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents . Cancer Res. , 54 , 58245830 ( 1994 ).
  • 52
    ) Kanamori , Y. , Kigawa , J. , Minagawa , Y. , Irie , T. , Oishi , T. , Shimada , M. , Takahashi , M. , Nakamura , T. , Sato , K. and Terakawa , N. A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53–deleted ovarian cancer cells . Eur. J. Cancer , 34 , 18021806 ( 1998 ).
  • 53
    ) Kyriakis , J. M. , Banerjee , P. , Nikolakaki , E. , Dai , T. , Rubie , E. A. , Ahmad , M. F. , Avruch , J. and Woodgett , J. R. The stress-activated protein kinase subfamily of c-Jun kinases . Nature , 369 , 156160 ( 1994 ).
  • 54
    ) Liu , Y. , Gorospe , M. , Yang , C. and Holbrook , N. J. Role of mitogen-activated protein kinase phosphatase during the cellular response to genotoxic stress. Inhibition of c-Jun N-terminal kinase activity and AP–1–dependent gene activation . J. Biol. Chem. , 270 , 83778380 ( 1995 ).
  • 55
    ) van Dam , H. , Wilhelm , D. , Herr , I. , Steffen , A. , Herrlich , P. and Angel , P. ATF–2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents . EMBOJ. , 14 , 17981811 ( 1995 ).
  • 56
    ) Seimiya , H. , Mashima , T. , Toho , M. and Tsuruo , T. c-Jun NH2–terminal kinase-mediated activation of interleukin–1beta converting enzyme/CED–3–like protease during anti-cancer drug-induced apoptosis . J. Biol. Chem. , 272 , 46314636 ( 1997 ).
  • 57
    ) Houghton , A. N. and Scheinberg , D. A. Monoclonal antibody therapies—a ‘constant’ threat to cancer . Nat. Med. , 6 , 373374 ( 2000 ).